Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2928 + anlotinib in relapsed/metastatic osteosarcoma and solid tumors
NCT06438783Phase 1Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tqb2928 in osteosarcoma (OS), dedifferentiated liposarcoma (DDL) and Liposarcoma (2 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Progression-Free Survival at 6 months and Overall Response Rate at 6 months. Started Feb 2024; status: terminated.
02
Drugs
tqb2928
03
Conditions
osteosarcoma (OS)dedifferentiated liposarcoma (DDL)Liposarcoma
Beyond the preview
Go deeper on NCT06438783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438783.